Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Melanoma 2Recurrence 1Prostatic Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × Interleukins × Clear all
NCT00089453 2012-04-19

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

University of Arkansas

Phase 1 Completed
10 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡